These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 17454035)

  • 41. The impact of formulation and process changes on in vitro dissolution and the bioequivalence of piroxicam capsules.
    Piscitelli DA; Bigora S; Propst C; Goskonda S; Schwartz P; Lesko LJ; Augsburger L; Young D
    Pharm Dev Technol; 1998 Nov; 3(4):443-52. PubMed ID: 9834946
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ultrasonically controlled release and targeted delivery of diclofenac sodium via gelatin magnetic microspheres.
    Saravanan M; Bhaskar K; Maharajan G; Pillai KS
    Int J Pharm; 2004 Sep; 283(1-2):71-82. PubMed ID: 15363503
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stereoselective interaction between piroxicam and acenocoumarol.
    Bonnabry P; Desmeules J; Rudaz S; Leemann T; Veuthey JL; Dayer P
    Br J Clin Pharmacol; 1996 Jun; 41(6):525-30. PubMed ID: 8799517
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of proniosomes as an alternative strategy to optimize piroxicam transdermal delivery.
    Alsarra IA
    J Microencapsul; 2009 May; 26(3):272-8. PubMed ID: 18720197
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biodegradable microspheres of poly(DL-lactic acid) containing piroxicam as a model drug for controlled release via the parenteral route.
    Lalla JK; Sapna K
    J Microencapsul; 1993; 10(4):449-60. PubMed ID: 8263674
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Coacervate Thermoresponsive Polysaccharide Nanoparticles as Delivery System for Piroxicam.
    Lachowicz D; Kaczyńska A; Bodzon-Kulakowska A; Karewicz A; Wirecka R; Szuwarzyński M; Zapotoczny S
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352956
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ethyl cellulose nanoparticles as a platform to decrease ulcerogenic potential of piroxicam: formulation and in vitro/in vivo evaluation.
    El-Habashy SE; Allam AN; El-Kamel AH
    Int J Nanomedicine; 2016; 11():2369-80. PubMed ID: 27307735
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of nonsteroidal anti-inflammatory drugs on glutathione S-transferases of the rat digestive tract.
    van Lieshout EM; Tiemessen DM; Peters WH; Jansen JB
    Carcinogenesis; 1997 Mar; 18(3):485-90. PubMed ID: 9067546
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The chitosan-gelatin (bio)polyelectrolyte complexes formation in an acidic medium.
    Voron'ko NG; Derkach SR; Kuchina YA; Sokolan NI
    Carbohydr Polym; 2016 Mar; 138():265-72. PubMed ID: 26794762
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effects of two polymeric matrices for indomethacin in cutaneous nociceptive reactivity in mice.
    Boancă M; Chiriac A; Niţă L; Novac O; Lupuşoru CE; Poroch V; Tarţău L
    Rev Med Chir Soc Med Nat Iasi; 2014; 118(1):125-32. PubMed ID: 24741788
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of selected formulation variables on the preparation of enzyme-entrapped Eudragit S100 microspheres.
    Rawat M; Saraf S; Saraf S
    AAPS PharmSciTech; 2007 Dec; 8(4):E116. PubMed ID: 18181537
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Innovation of novel sustained release compression-coated tablets for lornoxicam: formulation and in vitro investigations.
    Hamza Yel-S; Aburahma MH
    Drug Dev Ind Pharm; 2010 Mar; 36(3):337-49. PubMed ID: 19722915
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gelatin as a delivery vehicle for the controlled release of bioactive molecules.
    Young S; Wong M; Tabata Y; Mikos AG
    J Control Release; 2005 Dec; 109(1-3):256-74. PubMed ID: 16266768
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Square Wave Voltammetry: An Alternative Technique to Determinate Piroxicam Release Profiles from Nanostructured Lipid Carriers.
    Otarola J; Garrido M; Correa NM; Molina PG
    Chemphyschem; 2016 Aug; 17(15):2322-8. PubMed ID: 27128856
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An approach to a cold chain free oral cholera vaccine: in vitro and in vivo characterization of Vibrio cholerae gastro-resistant microparticles.
    Pastor M; Esquisabel A; Talavera A; Año G; Fernández S; Cedré B; Infante JF; Callicó A; Pedraz JL
    Int J Pharm; 2013 May; 448(1):247-58. PubMed ID: 23518363
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Colon specific CODES based Piroxicam tablet for colon targeting: statistical optimization, in vivo roentgenography and stability assessment.
    Singh AK; Pathak K
    Pharm Dev Technol; 2015 Mar; 20(2):237-45. PubMed ID: 24266719
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel gelatin microcapsule with bioavailability enhancement of ibuprofen using spray-drying technique.
    Li DX; Oh YK; Lim SJ; Kim JO; Yang HJ; Sung JH; Yong CS; Choi HG
    Int J Pharm; 2008 May; 355(1-2):277-84. PubMed ID: 18243606
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Polysaccharides based gastroretentive system to sustain piroxicam release: Development and in vivo prolonged anti-inflammatory effect.
    Auriemma G; Cerciello A; Sansone F; Pinto A; Morello S; Aquino RP
    Int J Biol Macromol; 2018 Dec; 120(Pt B):2303-2312. PubMed ID: 30171948
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hydroxypropyl methylcellulose microspheres with piroxicam and piroxicam-hydroxypropyl-beta-cyclodextrin inclusion complex.
    Jug M; Bećirević-Laćan M; Cetina-Cizmek B; Horvat M
    Pharmazie; 2004 Sep; 59(9):686-91. PubMed ID: 15497750
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preparation and characterization of free mixed-film of pectin/chitosan/Eudragit RS intended for sigmoidal drug delivery.
    Ghaffari A; Navaee K; Oskoui M; Bayati K; Rafiee-Tehrani M
    Eur J Pharm Biopharm; 2007 Aug; 67(1):175-86. PubMed ID: 17346954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.